Table 1.

Baseline characteristics of the participants

Patients with AVDs (n = 92)Patients without AVDs (n = 126)P value
Basic information
 Age (y)46.5 ± 11.251.6 ± 12.30.001
 Male (%)62.0%64.3%0.725
 Body mass index21.0 (19.4–23.0)22.1 (19.7–24.5)0.075
 Time since transplant (y)13.0 (7.4–17.0)9.7 (3.5–17.2)0.027
 Dialysis vintage (y)2.3 (1.1–4.9)2.1 (0.8–5.1)0.350
 ABO incompatibility0.106
  Compatible (%)82.6%70.6%
  Incompatible (%)8.7%17.5%
  No information (%)8.7%11.9%
 Living donor (%)82.6%86.5%0.428
 Donor age (y)51 (43–58)51 (40–60)0.679
Past history
 Diabetes0.008
  Type 2 (%)2.2%3.2%
  NODAT (%)5.4%19.8%
 Hepatitis C virus (%)3.3%4.0%0.784
 Previous cancer (%)9.8%7.1%0.484
Medication
 Calcineurin inhibitor0.393
  Cyclosporine (%)58.7%52.4%
  Tacrolimus (%)29.4%38.1%
  None (%)12.0%9.5%
 Antiproliferative agent0.028
  Azathioprine (%)31.5%15.9%
  Mycophenolate mofetil (%)44.6%60.3%
  Mizoribine (%)17.4%16.7%
  None (%)7.6%8.7%
 Predonisolone (%)97.8%97.6%0.920
 AVD analoguesN/A
  Calcitriol (%)58.7%N/A
  (μg/day)0.5 (0.5–0.5)N/A
  Alfacalcidol (%)41.3%N/A
  (μg/day)0.5 (0.25–1.0)N/A
Laboratory data
 Albumin (mg/dL)4.2 ± 0.34.3 ± 0.20.057
 Creatinine (mg/dL)1.54 (1.17–2.00)1.35 (1.02–1.74)0.011
 eGFR (mL/min per 1.73 m2)38.6 ± 15.243.3 ± 15.60.014
 Corrected calcium (mg/dL)9.3 ± 0.59.2 ± 0.50.787
 Phosphate (mg/dL)3.2 (2.8–3.6)3.1 (2.7–3.4)0.241
 Intact PTH (pg/mL)54.0 (36.7–85.1)72.7 (56.2–103.0)<0.001
 25(OH)D (ng/mL)18.0 (13.8–21.7)15.5 (11.7–21.1)0.051
 Urinary protein ≥30 mg/dL (%)54.4%45.2%0.184
Season of measurement0.006
 High UV-B season (%)45.7%63.5%
 Middle UV-B season (%)43.5%29.4%
 Low UV-B season (%)10.9%7.1%

NODAT, new-onset diabetes after transplantation; eGFR, estimated glomerular filtration rate.